Dianthus Therapeutics DNTH CMC Activities — Claseprubart Program Related Expenses

Similar metrics at other companies

CSL

CSLCCM — Research and development expenses

$8.4M+3.7%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

AMRXAffordable Medicines — Product development and studies

-$1M+37.5%

BIIBClinical Inventory — Cost of sales, excluding amortization and impairment of acquired intangible assets

$56.8M+851%

MIRMReportable Segment — Commercialization and Medical Affairs expenses (excluding stock-based compensation)

$44.22M+23.6%

LQD

LQDAGeneric Treprostinil — Program Expenses

-$49K-132%

Questions, answered.

What is Dianthus Therapeutics's CMC activities — claseprubart program related expenses?

Dianthus Therapeutics (DNTH) reported CMC activities — claseprubart program related expenses of $3.71M in Q1 2026.

What does CMC activities — claseprubart program related expenses mean?

This metric represents the aggregate costs associated with Chemistry, Manufacturing, and Controls (CMC) activities specifically allocated to the development of the claseprubart therapeutic program. These expenses encompass the processes required to ensure product quality, scalability, and regulatory compliance during clinical development phases. Tracking these costs provides insight into the capital intensity and manufacturing readiness of the specific drug candidate.